Bio-Techne Corp (NASDAQ:TECH) files its latest 10-K with SEC for the fiscal year ended on June 30, 2019. Bio-Techne Corp and is a biotechnology company which develops, manufactures and sells biotechnology reagents, instruments and clinical diagnostic products. Bio-Techne Corp has a market cap of $7.22 billion; its shares were traded at around $190.60 with a P/E ratio of 77.17 and P/S ratio of 10.53. The dividend yield of Bio-Techne Corp stocks is 0.68%. Bio-Techne Corp had annual average EBITDA growth of 2.60% over the past ten years. GuruFocus rated Bio-Techne Corp the business predictability rank of 3-star. GuruFocus has detected 3 severe warning signs with Bio-Techne Corp. .
For the last quarter Bio-Techne Corp reported a revenue of $191.7 million, compared with the revenue of $180.3 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $714.0 million, an increase of 11% from last year. For the complete 30-year financial data, please go here.. For the last five years Bio-Techne Corp had an average revenue growth rate of 14.2% a year.
The reported diluted earnings per share was $2.47 for the year, a decline of 25.4% from the previous year. Over the last five years Bio-Techne Corp had an average EPS decline of 2.5% a year. The Bio-Techne Corp had a decent operating margin of 20.55%, compared with the operating margin of 21.18% a year before. The 10-year historical median operating margin of Bio-Techne Corp is 47.84%. The profitability rank of the company is 8 (out of 10).
At the end of the fiscal year, Bio-Techne Corp has the cash and cash equivalents of $100.9 million, compared with $122.0 million in the previous year. The long term debt was $492.7 million, compared with $339.0 million in the previous year. Bio-Techne Corp has a financial strength rank of 6 (out of 10).
At the current stock price of $190.60, Bio-Techne Corp is traded at 21.5% premium to its historical median P/S valuation band of $156.83. The P/S ratio of the stock is 10.53, while the historical median P/S ratio is 8.64. The intrinsic value of the stock is $26.43 a share, according to GuruFocus DCF Calculator. The stock gained 1.53% during the past 12 months.
Directors and Officers Recent Trades:
- Director Robert V Baumgartner bought 500 shares of TECH stock on 08/07/2019 at the average price of $191.06. The price of the stock has decreased by 0.24% since.
For the complete 20-year historical financial data of TECH, click here.
This article first appeared on GuruFocus.
- Warning! GuruFocus has detected 5 Warning Signs with TECH. Click here to check it out.
- TECH 15-Year Financial Data
- The intrinsic value of TECH
- Peter Lynch Chart of TECH